Recent Finacing
Recent Raise
Symbiotix Biotherapies develops microbiome-derived molecular therapeutics (Reglemers/PSA) that activate regulatory T cells, producing oral candidates for IBD, multiple sclerosis, and other immune-mediated diseases.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors